{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:03Z","timestamp":1787772363402,"version":"build-2784847793"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>The objective of the study was to assess the efficacy and safety profiles of combined treatment of prednisolone with thalidomide (Gr-A) and prednisolone with clofazimine (Gr. B) in patients with erythema nodosum leprosum (ENL) or type 2 lepra reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>Efficacy of both regimens was assessed on the basis of clinical recovery of recurrent ENL measured by reaction severity score (RSS), Visual Analog Scale (VAS), and recurrence of type 2 lepra reaction. The causality assessment of adverse drug reactions was done using the WHO UMC causality assessment scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      The average age of patients with recurrent ENL was 42.8 years (male) and 51.8yrs (female) and had mean duration of leprosy and recurrent ENL 2.4 years and 2.09 years, respectively. 80% of nonrecurrence was observed in Gr-A versus 66% in Gr-B. Significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) lower RSS and VAS was found in both the treatment groups as compared to pretreatment value. The reduction in RSS and VAS was statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) in Gr-A compared to Gr-B treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Thalidomide combination with steroid was found to be more efficacious than clofazimine combination with steroid in the treatment of ENL both the treatment regimens showed few tolerable side effects. Improved strategies for the treatment and management of these reactions need to be developed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_946_21","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:51:03Z","timestamp":1716479463000},"page":"177-182","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Thalidomide and steroid in the management of erythema nodosum leprosum"],"prefix":"10.4103","volume":"54","author":[{"given":"S. R. P. K.","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashree","family":"Samal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240903","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.trstmh.2008.01.004","article-title":"Towards understanding the pathology of erythema nodosum leprosum","volume":"102","author":"Kahawita","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R2-4-20240903","doi-asserted-by":"crossref","first-page":"868","DOI":"10.4269\/ajtmh.2006.74.868","article-title":"Clinical course of erythema nodosum leprosum: An 11 year cohort in Hyderabad, India","volume":"74","author":"Pocaterra","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"R3-4-20240903","first-page":"10","article-title":"Leprosy reactions-complications of steroid therapy","volume":"66","author":"Sugumaran","year":"1998","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"R4-4-20240903","first-page":"501","article-title":"Translation: Thalidomide: Mechanism of action, side effects and therapeutic use","volume":"73","author":"Penna","year":"1998","journal-title":"An Bras Dermatol"},{"key":"R5-4-20240903","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0167-5699(99)01531-5","article-title":"Thalidomide as an emerging immunotherapeutic agent","volume":"20","author":"Marriott","year":"1999","journal-title":"Immunol Today"},{"key":"R6-4-20240903","first-page":"632","article-title":"Translation: Sbd contribution to the review of ordinance 354 August 1997 an bras dermatol 2001 76 632 3","volume":"76","author":"Penna","year":"2001","journal-title":"An Bras Dermatol"},{"key":"R7-4-20240903","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3959(87)90006-6","article-title":"Development of a questionnaire for the assessment of active and passive coping strategies in chronic pain patients","volume":"31","author":"Brown","year":"1987","journal-title":"Pain"},{"key":"R8-4-20240903","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/bmj.38107.645926.AE","article-title":"Steroid prophylaxis for prevention of nerve function impairment in leprosy: Randomized placebo controlled trial (TRIPOD 1)","volume":"328","author":"Smith","year":"2004","journal-title":"BMJ"},{"key":"R9-4-20240903","first-page":"S21","article-title":"Bangkok Workshop on Leprosy Research","volume":"64","author":"Naafs","year":"1996","journal-title":"Treatment of reactions and nerve damage. Int J Lepr Other Mycobact Dis"},{"key":"R10-4-20240903","doi-asserted-by":"crossref","first-page":"221","DOI":"10.47276\/lr.87.2.221","article-title":"The use of steroids and thalidomide in the management of Erythema Nodosum Leprosum; 17 years at the Hospital for Tropical Diseases, London","volume":"87","author":"Nabarro","year":"2016","journal-title":"Lepr Rev"},{"key":"R11-4-20240903","first-page":"29","article-title":"Comparative efficacy of four treatment regimens in type 2 leprosy reactions (Prednisolone alone, Thalidomide alone, Prednisolone plus Thalidomide and Prednisolone plus Clofazimine)","volume":"88","author":"Kar","year":"2016","journal-title":"Indian J Lepr"},{"key":"R12-4-20240903","doi-asserted-by":"crossref","first-page":"e2690","DOI":"10.1371\/journal.pntd.0002690","article-title":"The mortality associated with Erythema Nodosum Leprosum in Ethiopia: Retrospective hospital based study published in PLOS","volume":"8","author":"Walker","year":"2014","journal-title":"Neglected Tropical Diseases"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_946_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:40:38Z","timestamp":1787769638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_946_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_946_21","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}